Blume Capital Management’s Amgen AMGN Stock Holding History

Blume Capital Management’s Portfolio AMGN Stock Details AMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$192K	Hold	530	–	–	0.03%	123
2026 Q1	$186K	Hold	530	–	–	0.03%	115
2025 Q4	$173K	Hold	530	–	–	0.03%	121
2025 Q3	$150K	Hold	530	–	–	0.03%	131
2025 Q2	$148K	Sell	530 -2	-0.4%	-$567	0.03%	128
2025 Q1	$166K	Buy	532 +2	+0.4%	+$591	0.04%	118
2024 Q4	$138K	Hold	530	–	–	0.03%	127
2024 Q3	$171K	Sell	530 -25	-5%	-$8.18K	0.04%	121
2024 Q2	$173K	Hold	555	–	–	0.04%	113
2024 Q1	$158K	Hold	555	–	–	0.04%	118
2023 Q4	$160K	Hold	555	–	–	0.04%	104
2023 Q3	$149K	Hold	555	–	–	0.04%	107
2023 Q2	$123K	Hold	555	–	–	0.04%	117
2023 Q1	$134K	Hold	555	–	–	0.04%	103
2022 Q4	$146K	Hold	555	–	–	0.05%	104
2022 Q3	$125K	Sell	555 -3	-0.5%	-$727	0.05%	98
2022 Q2	$136K	Buy	558 +36	+7%	+$8.82K	0.05%	100
2022 Q1	$126K	Hold	522	–	–	0.04%	112
2021 Q4	$117K	Hold	522	–	–	0.04%	132
2021 Q3	$111K	Hold	522	–	–	0.04%	124
2021 Q2	$127K	Hold	522	–	–	0.05%	112
2021 Q1	$130K	Buy	522 +122	+31%	+$29.1K	0.05%	97
2020 Q4	$92K	Hold	400	–	–	0.04%	98
2020 Q3	$102K	Hold	400	–	–	0.05%	93
2020 Q2	$94K	Hold	400	–	–	0.05%	90
2020 Q1	$81K	Hold	400	–	–	0.05%	89
2019 Q4	$96K	Hold	400	–	–	0.05%	98
2019 Q3	$77K	Hold	400	–	–	0.04%	105
2019 Q2	$74K	Hold	400	–	–	0.04%	103
2019 Q1	$76K	Hold	400	–	–	0.04%	107
2018 Q4	$78K	Hold	400	–	–	0.04%	104
2018 Q3	$83K	Hold	400	–	–	0.04%	92
2018 Q2	$74K	Hold	400	–	–	0.04%	90
2018 Q1	$68K	Hold	400	–	–	0.04%	102
2017 Q4	$70K	Hold	400	–	–	0.04%	105
2017 Q3	$75K	Hold	400	–	–	0.04%	95
2017 Q2	$69K	Hold	400	–	–	0.04%	88
2017 Q1	$66K	Hold	400	–	–	0.04%	86
2016 Q4	$58K	Sell	400 -25	-6%	-$3.76K	0.03%	90
2016 Q3	$71K	Hold	425	–	–	0.04%	79
2016 Q2	$65K	Hold	425	–	–	0.04%	85
2016 Q1	$64K	Buy	425 +25	+6%	+$3.71K	0.04%	86
2015 Q4	$65K	Hold	400	–	–	0.05%	90
2015 Q3	$55K	Sell	400 -100	-20%	-$15.8K	0.04%	91
2015 Q2	$77K	Sell	500 -736	-60%	-$118K	0.06%	83
2015 Q1	$198K	Buy	1,236 +300	+32%	+$47.2K	0.14%	53
2014 Q4	$149K	Buy	936 +436	+87%	+$67.9K	0.11%	65
2014 Q3	$70K	Hold	500	–	–	0.05%	79
2014 Q2	$59K	Hold	500	–	–	0.05%	92
2014 Q1	$62K	Hold	500	–	–	0.05%	92
2013 Q4	$57K	Buy	+500	New	+$56.9K	0.05%	104

Other funds holding AMGN

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

FFM

Forum Financial Management Lombard, Illinois $7.79B AUM 20.38% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Sarasin & Partners London, United Kingdom $8.54B AUM 9.6% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.2B AUM 38.15% 1-Year Est. Return

Blume Capital Management's AMGN Position: Q2 2026 in Review

Blume Capital Management held its Amgen (AMGN) position steady in Q2 2026 at 530 shares worth $192K. The position accounts for 0.03% of the portfolio, ranked #123.

Blume Capital Management first reported a position in AMGN in Q4 2013 and has held it in 51 quarters since. The position peaked at $198K in Q1 2015. 1,242 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

Blume Capital Management held 530 shares of Amgen worth $192K as of Q2 2026.
Blume Capital Management left its Amgen share count unchanged in Q2 2026.
Amgen made up 0.03% of Blume Capital Management's portfolio in Q2 2026, its #123 holding.
Blume Capital Management first reported a position in Amgen in Q4 2013 and has held it in 51 quarters since.
Blume Capital Management's Amgen position peaked at $198K in Q1 2015.
1,242 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Blume Capital Management's 13F filing for Q2 2026, filed 27 Jul 2026.